Rujun Gong Selected Research

Nephrotic Syndrome (Syndrome, Nephrotic)

1/2020	Relapse of Nephrotic Syndrome after Adrenocorticotropic Hormone-Induced Remission: Implications of Adrenocorticotropic Hormone Antibodies.
1/2020	Melanocortin therapy ameliorates podocytopathy and proteinuria in experimental focal segmental glomerulosclerosis involving a podocyte specific non-MC1R-mediated melanocortinergic signaling.
7/2017	Acquired Resistance to Corticotropin Therapy in Nephrotic Syndrome: Role of De Novo Neutralizing Antibody.
1/2016	MC1R is dispensable for the proteinuria reducing and glomerular protective effect of melanocortin therapy.
3/2014	Leveraging melanocortin pathways to treat glomerular diseases.
12/2011	The renaissance of corticotropin therapy in proteinuric nephropathies.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Rujun Gong Research Topics

Disease

18	Proteinuria 01/2022 - 11/2004
17	Fibrosis (Cirrhosis) 01/2021 - 12/2003
13	Acute Kidney Injury (Acute Renal Failure) 12/2022 - 01/2011
13	Inflammation (Inflammations) 10/2020 - 11/2004
11	Chronic Renal Insufficiency 01/2019 - 12/2003
6	Albuminuria 11/2021 - 11/2015
6	Nephrotic Syndrome (Syndrome, Nephrotic) 01/2020 - 12/2011
5	Focal Segmental Glomerulosclerosis (Glomerulosclerosis, Focal) 01/2022 - 03/2014
4	Kidney Diseases (Kidney Disease) 01/2021 - 03/2008
4	Diabetic Nephropathies (Diabetic Nephropathy) 01/2020 - 01/2019
4	Necrosis 10/2018 - 04/2012
4	Ischemia 11/2016 - 07/2013
4	Neoplasms (Cancer) 01/2016 - 10/2013
3	Nephritis 02/2023 - 03/2015
3	Lipoid Nephrosis (Glomerulonephritis, Minimal Change) 01/2022 - 03/2014
3	Body Weight (Weight, Body) 01/2021 - 03/2013
3	Atrophy 01/2021 - 11/2016
3	Sclerosis 01/2019 - 01/2012
3	Hepatocellular Carcinoma (Hepatoma) 07/2014 - 04/2013
3	Ureteral Obstruction 05/2012 - 08/2010
2	Membranous Glomerulonephritis (Membranous Nephropathy) 01/2023 - 03/2014
2	Reperfusion Injury 12/2022 - 11/2015
2	Infections 01/2021 - 01/2015
2	Mood Disorders (Mood Disorder) 01/2021 - 12/2016
2	Chronic Kidney Failure (Chronic Renal Failure) 01/2020 - 04/2005
2	Wounds and Injuries (Trauma) 01/2019 - 02/2015
2	Mitochondrial Diseases (Mitochondrial Disease) 05/2015 - 02/2015
2	Vascular System Injuries 01/2012 - 01/2005
2	Lupus Nephritis 05/2007 - 02/2002
1	Type 2 Diabetes Mellitus (MODY) 03/2024
1	Nephrosis 01/2022
1	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 01/2021
1	Hyperglycemia 01/2021
1	Acne Vulgaris 10/2020
1	Experimental Melanoma 01/2020

Drug/Important Bio-Agent (IBA)

11	Adrenocorticotropic Hormone (ACTH)FDA Link 02/2023 - 12/2011
10	Glycogen Synthase KinasesIBA 01/2021 - 04/2012
9	MelanocortinsIBA 02/2023 - 03/2014
9	Peptides (Polypeptides)IBA 01/2022 - 01/2005
9	LithiumIBA 01/2021 - 03/2014
6	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2020 - 10/2014
6	Hepatocyte Growth Factor (Growth Factor, Hepatocyte)IBA 03/2008 - 12/2003
5	Melanocortin Receptors (Melanocortin Receptor)IBA 02/2023 - 01/2016
5	SteroidsIBA 01/2022 - 12/2011
5	Folic Acid (Vitamin M)FDA LinkGeneric 01/2021 - 08/2014
5	CytokinesIBA 01/2020 - 03/2008
4	Cisplatin (Platino)FDA LinkGeneric 12/2022 - 03/2014
4	AntioxidantsIBA 01/2019 - 11/2008
4	AldosteroneIBA 05/2015 - 09/2011
4	CollagenIBA 01/2015 - 12/2003
4	SurvivinIBA 07/2014 - 04/2013
3	Proteins (Proteins, Gene)FDA Link 03/2024 - 11/2015
3	Immunoglobulin G (IgG)IBA 02/2023 - 11/2004
3	Hormones (Hormone)IBA 01/2021 - 03/2014
3	Mineralocorticoid Receptors (Mineralocorticoid Receptor)IBA 01/2019 - 05/2015
3	4- benzyl- 2- methyl- 1,2,4- thiadiazolidine- 3,5- dioneIBA 06/2015 - 04/2012
3	ErbB Receptors (EGF Receptor)IBA 07/2013 - 01/2012
3	NF-kappa B (NF-kB)IBA 01/2012 - 11/2004
2	Type 1 Melanocortin ReceptorIBA 02/2023 - 01/2023
2	4-Nle-7-Phe-alpha- MSHIBA 02/2023 - 01/2016
2	Heme (Haem)IBA 12/2022 - 01/2015
2	Streptozocin (Streptozotocin)FDA Link 11/2021 - 01/2021
2	AntigensIBA 01/2020 - 03/2012
2	AntibodiesIBA 01/2020 - 07/2017
2	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 10/2018 - 03/2010
2	Immunosuppressive Agents (Immunosuppressants)IBA 07/2017 - 12/2011
2	Neutralizing AntibodiesIBA 07/2017 - 12/2003
2	tanshinoneIBA 11/2016 - 01/2015
2	Fibronectins (Fibronectin)IBA 11/2016 - 01/2015
2	Phosphotransferases (Kinase)IBA 11/2015 - 01/2012
2	Growth Factor ReceptorsIBA 05/2015 - 01/2012
2	Extracellular Matrix ProteinsIBA 07/2013 - 08/2010
2	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 01/2012 - 12/2010
2	ChemokinesIBA 12/2010 - 11/2004
2	candesartanIBA 11/2008 - 03/2007
2	Fibrinogen (Factor I)FDA Link 05/2007 - 02/2002
2	Plasminogen Activator Inhibitor 1IBA 05/2007 - 02/2002
2	Plasminogen Activators (Plasminogen Activator)IBA 12/2003 - 02/2002
1	GalactosidasesIBA 03/2024
1	Complement Membrane Attack Complex (Membrane Attack Complex)IBA 02/2023
1	NeuropeptidesIBA 01/2023
1	IronIBA 12/2022
1	HemopexinIBA 12/2022
1	Hemoglobins (Hemoglobin)IBA 12/2022
1	melanocortin 5 receptorIBA 01/2022
1	Puromycin AminonucleosideIBA 01/2022
1	Hypoglycemic Agents (Hypoglycemics)IBA 01/2021
1	TristetraprolinIBA 01/2020
1	thiamine triphosphorate (TTP)IBA 01/2020
1	Cyclosporine (Ciclosporin)FDA LinkGeneric 01/2020
1	NPHS2 proteinIBA 01/2020
1	Insulin (Novolin)FDA Link 01/2020
1	triptolideIBA 01/2020
1	RNA-Binding Proteins (RNA-Binding Protein)IBA 01/2020
1	Biomarkers (Surrogate Marker)IBA 01/2020

Therapy/Procedure

23	Therapeutics 02/2023 - 12/2011
3	Nephrectomy 01/2012 - 11/2004
2	Immunomodulation 10/2020 - 03/2014
2	Treatment Delay 11/2016 - 03/2014
1	Artificial Respiration (Mechanical Ventilation) 01/2021